nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—AGTR1—atherosclerosis	0.703	1	CbGaD
Tasosartan—CYP3A4—Rosuvastatin—atherosclerosis	0.0293	0.211	CbGbCtD
Tasosartan—CYP3A4—Ezetimibe—atherosclerosis	0.0293	0.211	CbGbCtD
Tasosartan—CYP3A4—Simvastatin—atherosclerosis	0.0272	0.196	CbGbCtD
Tasosartan—CYP3A4—Pravastatin—atherosclerosis	0.0267	0.192	CbGbCtD
Tasosartan—CYP3A4—Lovastatin—atherosclerosis	0.0267	0.192	CbGbCtD
Tasosartan—AGTR2—cardiovascular system—atherosclerosis	0.00641	0.239	CbGeAlD
Tasosartan—AGTR1—artery—atherosclerosis	0.00413	0.154	CbGeAlD
Tasosartan—AGTR2—liver—atherosclerosis	0.00396	0.148	CbGeAlD
Tasosartan—AGTR1—endothelium—atherosclerosis	0.00349	0.13	CbGeAlD
Tasosartan—AGTR1—blood vessel—atherosclerosis	0.00322	0.12	CbGeAlD
Tasosartan—Azilsartan medoxomil—AGTR1—atherosclerosis	0.00168	0.211	CrCbGaD
Tasosartan—AGTR1—connective tissue—atherosclerosis	0.00165	0.0616	CbGeAlD
Tasosartan—Forasartan—AGTR1—atherosclerosis	0.00156	0.196	CrCbGaD
Tasosartan—AGTR1—cardiovascular system—atherosclerosis	0.00143	0.0536	CbGeAlD
Tasosartan—AGTR1—adipose tissue—atherosclerosis	0.00127	0.0473	CbGeAlD
Tasosartan—Irbesartan—EDNRA—atherosclerosis	0.000932	0.117	CrCbGaD
Tasosartan—AGTR1—liver—atherosclerosis	0.000887	0.0331	CbGeAlD
Tasosartan—Valsartan—AGTR1—atherosclerosis	0.00082	0.103	CrCbGaD
Tasosartan—Olmesartan—AGTR1—atherosclerosis	0.000799	0.1	CrCbGaD
Tasosartan—Irbesartan—AGTR1—atherosclerosis	0.000622	0.0781	CrCbGaD
Tasosartan—Candesartan—AGTR1—atherosclerosis	0.000622	0.0781	CrCbGaD
Tasosartan—Losartan—AGTR1—atherosclerosis	0.000401	0.0503	CrCbGaD
Tasosartan—CYP3A4—liver—atherosclerosis	0.000326	0.0122	CbGeAlD
Tasosartan—Losartan—ACE—atherosclerosis	0.000231	0.0291	CrCbGaD
Tasosartan—Valsartan—ALB—atherosclerosis	0.000194	0.0244	CrCbGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP7A1—atherosclerosis	0.000162	0.00131	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CCL5—atherosclerosis	0.000162	0.00131	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CNR2—atherosclerosis	0.000156	0.00126	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CXCL8—atherosclerosis	0.000156	0.00126	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—MMP3—atherosclerosis	0.000155	0.00126	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—AGT—atherosclerosis	0.000154	0.00125	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—PRKCG—atherosclerosis	0.000154	0.00124	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—AGT—atherosclerosis	0.000153	0.00124	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—atherosclerosis	0.00015	0.00122	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—atherosclerosis	0.00015	0.00121	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—HRH1—atherosclerosis	0.00015	0.00121	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TGFB1—atherosclerosis	0.000149	0.00121	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—EDN1—atherosclerosis	0.000148	0.0012	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCL5—atherosclerosis	0.000147	0.00119	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.000146	0.00119	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL3—atherosclerosis	0.000144	0.00117	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—F2—atherosclerosis	0.000143	0.00116	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—F2—atherosclerosis	0.000141	0.00114	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TNF—atherosclerosis	0.00014	0.00113	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PRKCG—atherosclerosis	0.000139	0.00113	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—VWF—atherosclerosis	0.000139	0.00113	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	0.000138	0.00112	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—APOC3—atherosclerosis	0.000138	0.00112	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LDLR—atherosclerosis	0.000137	0.00111	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—AGT—atherosclerosis	0.000135	0.0011	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL3—atherosclerosis	0.000134	0.00109	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—EDNRA—atherosclerosis	0.00013	0.00106	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCR2—atherosclerosis	0.00013	0.00106	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NCF1—atherosclerosis	0.000128	0.00104	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	0.000128	0.00103	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GHRL—atherosclerosis	0.000127	0.00103	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCL2—atherosclerosis	0.000126	0.00102	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—F2—atherosclerosis	0.000125	0.00101	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000123	0.000999	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—AGT—atherosclerosis	0.000123	0.000995	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.000122	0.000991	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCR2—atherosclerosis	0.000121	0.000982	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EDNRA—atherosclerosis	0.000121	0.000982	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CYBA—atherosclerosis	0.000121	0.000978	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000119	0.000968	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PARP1—atherosclerosis	0.000118	0.000957	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PLAT—atherosclerosis	0.000118	0.000957	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GHRL—atherosclerosis	0.000118	0.000957	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—F2—atherosclerosis	0.000113	0.000919	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atherosclerosis	0.000113	0.000914	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—KNG1—atherosclerosis	0.000111	0.000903	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PIK3CG—atherosclerosis	0.000109	0.000879	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL4—atherosclerosis	0.000108	0.000877	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—UTS2—atherosclerosis	0.000106	0.00086	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—KNG1—atherosclerosis	0.000104	0.00084	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AGTR1—atherosclerosis	0.000103	0.000835	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.000102	0.000829	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CASR—atherosclerosis	0.000102	0.000825	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCL2—atherosclerosis	0.000101	0.000819	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PLG—atherosclerosis	0.0001	0.000814	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CXCL8—atherosclerosis	9.93e-05	0.000805	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—UTS2—atherosclerosis	9.64e-05	0.000781	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SOCS3—atherosclerosis	9.51e-05	0.000771	CbGpPWpGaD
Tasosartan—Losartan—ALB—atherosclerosis	9.48e-05	0.0119	CrCbGaD
Tasosartan—AGTR1—GPCR downstream signaling—CNR2—atherosclerosis	9.46e-05	0.000767	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	9.45e-05	0.000766	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—EDN1—atherosclerosis	9.39e-05	0.000761	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—atherosclerosis	9.32e-05	0.000756	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL5—atherosclerosis	9.31e-05	0.000755	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CX3CR1—atherosclerosis	9.24e-05	0.000749	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CASR—atherosclerosis	9.24e-05	0.000749	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MMP3—atherosclerosis	9.18e-05	0.000744	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IGF2—atherosclerosis	9.14e-05	0.000741	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CX3CL1—atherosclerosis	9.06e-05	0.000735	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—APOB—atherosclerosis	8.87e-05	0.000719	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HRH1—atherosclerosis	8.84e-05	0.000716	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CXCL8—atherosclerosis	8.8e-05	0.000713	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EDN1—atherosclerosis	8.73e-05	0.000708	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL5—atherosclerosis	8.67e-05	0.000702	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP7A1—atherosclerosis	8.62e-05	0.000698	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CNR2—atherosclerosis	8.59e-05	0.000696	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP7A1—atherosclerosis	8.5e-05	0.000689	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LPL—atherosclerosis	8.47e-05	0.000687	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	8.43e-05	0.000683	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PRKCG—atherosclerosis	8.24e-05	0.000668	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SPP1—atherosclerosis	8.03e-05	0.00065	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CXCL8—atherosclerosis	7.99e-05	0.000648	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP27A1—atherosclerosis	7.96e-05	0.000645	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP27A1—atherosclerosis	7.85e-05	0.000637	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—AGT—atherosclerosis	7.79e-05	0.000631	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PDGFB—atherosclerosis	7.43e-05	0.000602	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL3—atherosclerosis	7.39e-05	0.000599	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—EDNRA—atherosclerosis	7.36e-05	0.000596	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CCR2—atherosclerosis	7.36e-05	0.000596	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AGT—atherosclerosis	7.25e-05	0.000588	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—F2—atherosclerosis	7.2e-05	0.000584	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GHRL—atherosclerosis	7.17e-05	0.000581	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LEP—atherosclerosis	7.1e-05	0.000576	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—APOE—atherosclerosis	7.1e-05	0.000576	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CAV1—atherosclerosis	7.04e-05	0.00057	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—APOA1—atherosclerosis	7.02e-05	0.000569	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOA4—atherosclerosis	6.94e-05	0.000562	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	6.91e-05	0.00056	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ESR1—atherosclerosis	6.78e-05	0.00055	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—F2—atherosclerosis	6.7e-05	0.000543	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCR2—atherosclerosis	6.68e-05	0.000542	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EDNRA—atherosclerosis	6.68e-05	0.000542	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	6.66e-05	0.00054	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GHRL—atherosclerosis	6.51e-05	0.000528	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL2—atherosclerosis	6.42e-05	0.00052	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PIK3CG—atherosclerosis	6.41e-05	0.00052	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL4—atherosclerosis	6.39e-05	0.000518	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—KNG1—atherosclerosis	6.29e-05	0.00051	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—MAPK3—atherosclerosis	6.14e-05	0.000498	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—INS—atherosclerosis	6.07e-05	0.000492	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOA2—atherosclerosis	5.97e-05	0.000484	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL2—atherosclerosis	5.97e-05	0.000484	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IGF1—atherosclerosis	5.87e-05	0.000476	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—KNG1—atherosclerosis	5.72e-05	0.000463	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—UTS2—atherosclerosis	5.7e-05	0.000462	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SERPINE1—atherosclerosis	5.57e-05	0.000452	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CX3CR1—atherosclerosis	5.46e-05	0.000443	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CASR—atherosclerosis	5.46e-05	0.000443	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CX3CL1—atherosclerosis	5.35e-05	0.000434	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NOS3—atherosclerosis	5.32e-05	0.000431	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—EDN1—atherosclerosis	5.3e-05	0.00043	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CCL5—atherosclerosis	5.26e-05	0.000427	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CNR2—atherosclerosis	5.08e-05	0.000411	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CXCL8—atherosclerosis	5.07e-05	0.000411	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—MMP3—atherosclerosis	5.06e-05	0.00041	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	5.05e-05	0.00041	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PRKCG—atherosclerosis	5e-05	0.000406	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EDN1—atherosclerosis	4.82e-05	0.00039	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL5—atherosclerosis	4.78e-05	0.000387	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CXCL8—atherosclerosis	4.72e-05	0.000383	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—AKT1—atherosclerosis	4.56e-05	0.00037	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PRKCG—atherosclerosis	4.54e-05	0.000368	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—VWF—atherosclerosis	4.52e-05	0.000367	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOC3—atherosclerosis	4.5e-05	0.000364	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL6—atherosclerosis	4.49e-05	0.000364	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LDLR—atherosclerosis	4.47e-05	0.000362	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—AGT—atherosclerosis	4.4e-05	0.000357	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL3—atherosclerosis	4.37e-05	0.000354	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MMP9—atherosclerosis	4.27e-05	0.000346	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NFKB1—atherosclerosis	4.22e-05	0.000342	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NCF1—atherosclerosis	4.18e-05	0.000339	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MAPK8—atherosclerosis	4.15e-05	0.000337	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—AKT1—atherosclerosis	4.14e-05	0.000336	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—F2—atherosclerosis	4.07e-05	0.00033	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—AGT—atherosclerosis	4e-05	0.000324	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCR2—atherosclerosis	3.95e-05	0.00032	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EDNRA—atherosclerosis	3.95e-05	0.00032	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CYBA—atherosclerosis	3.93e-05	0.000319	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PIK3CG—atherosclerosis	3.89e-05	0.000316	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PLAT—atherosclerosis	3.85e-05	0.000312	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PARP1—atherosclerosis	3.85e-05	0.000312	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GHRL—atherosclerosis	3.85e-05	0.000312	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—VEGFA—atherosclerosis	3.83e-05	0.000311	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—STAT3—atherosclerosis	3.8e-05	0.000308	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—F2—atherosclerosis	3.69e-05	0.000299	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MAPK3—atherosclerosis	3.63e-05	0.000294	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	3.56e-05	0.000288	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PIK3CG—atherosclerosis	3.54e-05	0.000287	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TGFB1—atherosclerosis	3.52e-05	0.000285	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	3.51e-05	0.000284	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—KNG1—atherosclerosis	3.38e-05	0.000274	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL2—atherosclerosis	3.29e-05	0.000267	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PLG—atherosclerosis	3.27e-05	0.000265	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SOCS3—atherosclerosis	3.1e-05	0.000251	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MMP3—atherosclerosis	2.99e-05	0.000242	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF2—atherosclerosis	2.98e-05	0.000241	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOB—atherosclerosis	2.89e-05	0.000234	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CXCL8—atherosclerosis	2.87e-05	0.000232	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EDN1—atherosclerosis	2.85e-05	0.000231	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL5—atherosclerosis	2.82e-05	0.000229	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LPL—atherosclerosis	2.76e-05	0.000224	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PRKCG—atherosclerosis	2.68e-05	0.000218	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL6—atherosclerosis	2.65e-05	0.000215	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SPP1—atherosclerosis	2.62e-05	0.000212	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CXCL8—atherosclerosis	2.6e-05	0.000211	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	2.52e-05	0.000204	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AKT1—atherosclerosis	2.45e-05	0.000198	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PDGFB—atherosclerosis	2.42e-05	0.000196	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PLTP—atherosclerosis	2.37e-05	0.000192	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AGT—atherosclerosis	2.36e-05	0.000191	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LEP—atherosclerosis	2.31e-05	0.000188	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOE—atherosclerosis	2.31e-05	0.000188	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CAV1—atherosclerosis	2.29e-05	0.000186	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOA1—atherosclerosis	2.29e-05	0.000185	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ESR1—atherosclerosis	2.21e-05	0.000179	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—F2—atherosclerosis	2.18e-05	0.000177	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PIK3CG—atherosclerosis	2.09e-05	0.000169	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LTA4H—atherosclerosis	2.06e-05	0.000167	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCG8—atherosclerosis	2.06e-05	0.000167	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—MAPK3—atherosclerosis	2e-05	0.000162	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—INS—atherosclerosis	1.98e-05	0.00016	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL2—atherosclerosis	1.95e-05	0.000158	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF1—atherosclerosis	1.91e-05	0.000155	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SERPINE1—atherosclerosis	1.82e-05	0.000147	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOS3—atherosclerosis	1.73e-05	0.000141	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.63e-05	0.000132	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CXCL8—atherosclerosis	1.54e-05	0.000125	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LCAT—atherosclerosis	1.53e-05	0.000124	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—FABP4—atherosclerosis	1.53e-05	0.000124	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOA4—atherosclerosis	1.5e-05	0.000122	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—AKT1—atherosclerosis	1.49e-05	0.00012	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.47e-05	0.000119	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL6—atherosclerosis	1.46e-05	0.000119	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MMP9—atherosclerosis	1.39e-05	0.000113	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NFKB1—atherosclerosis	1.38e-05	0.000112	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.36e-05	0.00011	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MAPK8—atherosclerosis	1.35e-05	0.00011	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—AKT1—atherosclerosis	1.35e-05	0.000109	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.29e-05	0.000105	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.29e-05	0.000105	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.29e-05	0.000105	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOA2—atherosclerosis	1.29e-05	0.000105	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.28e-05	0.000103	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—VEGFA—atherosclerosis	1.25e-05	0.000101	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—STAT3—atherosclerosis	1.24e-05	0.0001	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LPA—atherosclerosis	1.23e-05	9.98e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—BGN—atherosclerosis	1.19e-05	9.67e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MAPK3—atherosclerosis	1.18e-05	9.58e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOA5—atherosclerosis	1.18e-05	9.57e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TGFB1—atherosclerosis	1.15e-05	9.29e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.14e-05	9.21e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.1e-05	8.9e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NAMPT—atherosclerosis	9.85e-06	7.98e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LIPC—atherosclerosis	9.78e-06	7.93e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOC3—atherosclerosis	9.72e-06	7.88e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LDLR—atherosclerosis	9.66e-06	7.83e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CETP—atherosclerosis	9.44e-06	7.65e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SCARB1—atherosclerosis	9.04e-06	7.33e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL6—atherosclerosis	8.64e-06	7e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HMGCR—atherosclerosis	8.54e-06	6.92e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AKT1—atherosclerosis	7.97e-06	6.46e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCA1—atherosclerosis	7.61e-06	6.17e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HMOX1—atherosclerosis	6.53e-06	5.29e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOB—atherosclerosis	6.25e-06	5.07e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTM1—atherosclerosis	6.08e-06	4.93e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LPL—atherosclerosis	5.97e-06	4.84e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GPX1—atherosclerosis	5.83e-06	4.72e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CD36—atherosclerosis	5.67e-06	4.6e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MTHFR—atherosclerosis	5.38e-06	4.36e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PPARA—atherosclerosis	5.27e-06	4.27e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AGT—atherosclerosis	5.11e-06	4.14e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOE—atherosclerosis	5e-06	4.06e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CAV1—atherosclerosis	4.96e-06	4.02e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOA1—atherosclerosis	4.95e-06	4.01e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PIK3CG—atherosclerosis	4.52e-06	3.66e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PPARG—atherosclerosis	4.36e-06	3.53e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—INS—atherosclerosis	4.28e-06	3.47e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALB—atherosclerosis	3.92e-06	3.18e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NOS3—atherosclerosis	3.75e-06	3.04e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS2—atherosclerosis	3.43e-06	2.78e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AKT1—atherosclerosis	1.72e-06	1.4e-05	CbGpPWpGaD
